The White House is reportedly working to increase political oversight over the National Institutes of Health (NIH), the federal agency responsible for funding biomedical research in the United States. This move has sparked controversy, particularly with NIH director Jay Bhattacharya, who has opposed attempts to place research funding decisions under direct political control. Russell Vought, who leads the Office of Management and Budget (OMB), is spearheading the effort to exert more influence over how NIH research funds are allocated. According to reports from The Washington Post, Bhattacharya lost a heated internal White House meeting over the issue. This story has since been confirmed and expanded by The New York Times and Politico, which suggest that the administration is preparing an executive order that would give Vought the authority to veto every individual grant awarded by the NIH. Such a policy would represent a major shift in how research funding is managed, as the NIH traditionally operates with a high degree of independence in its grant decisions. The NIH is the largest single source of funding for biomedical research worldwide, with a budget of approximately $47 billion. This amount exceeds the combined budgets of the next 10 largest research funders. The agency’s funding is distributed primarily through grants to academic researchers at universities, supporting a wide range of scientific endeavors—from fundamental studies of biology to clinical trials testing new treatments. These grants have played a critical role in advancing medical science and fostering the growth of the biotechnology industry. Critics of the proposed changes argue that increasing political control over NIH grants could undermine the integrity of scientific research by introducing bias or favoritism into the funding process. Supporters, however, claim that greater oversight could ensure that taxpayer money is spent more effectively and in alignment with national priorities. The final decision on whether such an executive order will be issued remains pending, with the outcome likely to have significant implications for the future of medical research in the United States.